← back to search

Qilong Zhang

Harbin Medical University · CN
🔎 Find collaborators in Oncology · Pulmonary and Respiratory Medicine →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, Internal medicine, Oncology, Metastatic breast cancer, Fulvestrant, and Mycobacterium bovis.
h-index
citations
555
works
9
NIH funding
primary concept
email

Recent publications

Quantitative Proteome Analysis of Plasma Extracellular Vesicles Identifies Three Proteins with Potential Diagnostic Value for <i>Mycobacterium bovis</i> Infection in Cows
Journal of Proteome Research 2025cited by 0position: middledoi
Proteome overview of exosome derived from plasma of cows infected with Mycobacterium bovis
Tuberculosis 2024cited by 2position: middledoi
LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
Annals of Oncology 2023cited by 42position: middledoi
404P A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer
Annals of Oncology 2023cited by 1position: middledoi
LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial
Annals of Oncology 2022cited by 15position: middledoi
625MO Combination of mitoxantrone hydrochloride liposome with pegaspargase in patients with extranodal NK/T-cell lymphoma: A phase I/II clinical trial
Annals of Oncology 2022cited by 2position: middledoi
PCN38 Health-Related Quality of Life (QOL) in Monarch PLUS: A Phase 3 Trial of Abemaciclib PLUS Nonsteroidal Aromatase Inhibitor (NSAI) or Fulvestrant for Women with HR+/HER2- Advanced Breast Cancer (ABC)
Value in Health 2020cited by 2position: middledoi
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
Annals of Oncology 2019cited by 474position: middledoi
Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study
European Journal of Cancer Care 2017cited by 17position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Binghe Xu · Chinese Academy of Medical Sciences & Peking Union Medical College3 papers (2022–2023) · 2 papers (2024–2025)Yanshi Liu · Southwest Medical University2 papers (2019–2020)Hangfan Zhou · Ministry of Education of the People's Republic of China2 papers (2024–2025)Jiaqiang Zhu · University of Michigan–Ann Arbor2 papers (2024–2025)Yongqian Shu · Suzhou Municipal Hospital2 papers (2017–2019) · 2 papers (2024–2025)Lei Chang · Jiangnan University2 papers (2024–2025)Zhongsheng Tong · Tianjin Medical University Cancer Institute and Hospital2 papers (2020–2023) · 2 papers (2024–2025)Ping Xu · Guangzhou University of Chinese Medicine2 papers (2024–2025)W. Li · Ningbo University2 papers (2019–2022)Kevin Kalinsky · Emory University1 papers (2023–2023)Bing Hu · University of Waterloo1 papers (2017–2017)Yanfeng Gong · Fudan University1 papers (2022–2022)Chie‐Schin Shih · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2023–2023)Hou‐De Zhou · Nanchang University1 papers (2022–2022)Zhong Sheng Tong · Anhui Medical University1 papers (2022–2022)Baohui Han · Shanghai First People's Hospital1 papers (2017–2017) · 1 papers (2017–2017)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Pulmonary and Respiratory Medicine →